QQQ   444.36 (-0.11%)
AAPL   170.98 (-1.34%)
MSFT   420.41 (-0.24%)
META   486.27 (-1.54%)
GOOGL   150.50 (-0.25%)
AMZN   180.28 (+0.25%)
TSLA   176.57 (-1.81%)
NVDA   906.00 (+0.39%)
NIO   4.61 (-1.28%)
AMD   181.21 (+0.90%)
BABA   72.49 (+1.26%)
T   17.61 (+0.34%)
F   13.25 (+1.45%)
MU   118.18 (-0.81%)
CGC   9.70 (+1.57%)
GE   175.26 (-2.70%)
DIS   122.67 (+1.40%)
AMC   3.70 (-14.75%)
PFE   27.88 (+0.36%)
PYPL   67.20 (+0.95%)
XOM   115.76 (+0.69%)
QQQ   444.36 (-0.11%)
AAPL   170.98 (-1.34%)
MSFT   420.41 (-0.24%)
META   486.27 (-1.54%)
GOOGL   150.50 (-0.25%)
AMZN   180.28 (+0.25%)
TSLA   176.57 (-1.81%)
NVDA   906.00 (+0.39%)
NIO   4.61 (-1.28%)
AMD   181.21 (+0.90%)
BABA   72.49 (+1.26%)
T   17.61 (+0.34%)
F   13.25 (+1.45%)
MU   118.18 (-0.81%)
CGC   9.70 (+1.57%)
GE   175.26 (-2.70%)
DIS   122.67 (+1.40%)
AMC   3.70 (-14.75%)
PFE   27.88 (+0.36%)
PYPL   67.20 (+0.95%)
XOM   115.76 (+0.69%)
QQQ   444.36 (-0.11%)
AAPL   170.98 (-1.34%)
MSFT   420.41 (-0.24%)
META   486.27 (-1.54%)
GOOGL   150.50 (-0.25%)
AMZN   180.28 (+0.25%)
TSLA   176.57 (-1.81%)
NVDA   906.00 (+0.39%)
NIO   4.61 (-1.28%)
AMD   181.21 (+0.90%)
BABA   72.49 (+1.26%)
T   17.61 (+0.34%)
F   13.25 (+1.45%)
MU   118.18 (-0.81%)
CGC   9.70 (+1.57%)
GE   175.26 (-2.70%)
DIS   122.67 (+1.40%)
AMC   3.70 (-14.75%)
PFE   27.88 (+0.36%)
PYPL   67.20 (+0.95%)
XOM   115.76 (+0.69%)
QQQ   444.36 (-0.11%)
AAPL   170.98 (-1.34%)
MSFT   420.41 (-0.24%)
META   486.27 (-1.54%)
GOOGL   150.50 (-0.25%)
AMZN   180.28 (+0.25%)
TSLA   176.57 (-1.81%)
NVDA   906.00 (+0.39%)
NIO   4.61 (-1.28%)
AMD   181.21 (+0.90%)
BABA   72.49 (+1.26%)
T   17.61 (+0.34%)
F   13.25 (+1.45%)
MU   118.18 (-0.81%)
CGC   9.70 (+1.57%)
GE   175.26 (-2.70%)
DIS   122.67 (+1.40%)
AMC   3.70 (-14.75%)
PFE   27.88 (+0.36%)
PYPL   67.20 (+0.95%)
XOM   115.76 (+0.69%)
NASDAQ:INKT

MiNK Therapeutics (INKT) Stock Price, News & Analysis

$0.92
+0.01 (+0.99%)
(As of 12:15 PM ET)
Today's Range
$0.90
$0.92
50-Day Range
$0.84
$1.00
52-Week Range
$0.75
$3.34
Volume
23,192 shs
Average Volume
52,769 shs
Market Capitalization
$31.89 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.00

MiNK Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
889.0% Upside
$9.00 Price Target
Short Interest
Healthy
0.47% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.73mentions of MiNK Therapeutics in the last 14 days
Based on 17 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.59) to ($0.58) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.11 out of 5 stars

Medical Sector

634th out of 939 stocks

Biological Products, Except Diagnostic Industry

110th out of 156 stocks

INKT stock logo

About MiNK Therapeutics Stock (NASDAQ:INKT)

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. It's product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.

INKT Stock Price History

INKT Stock News Headlines

The AI Defense Stock Set to Soar
To protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.
MiNK Therapeutics (NASDAQ:INKT) PT Lowered to $9.00
The AI Defense Stock Set to Soar
To protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.
MiNK Reports Fourth Quarter and Year-End 2023 Results
Earnings Outlook For MiNK Therapeutics
MiNK Therapeutics Inc INKT
MiNK Therapeutics GAAP EPS of -$0.15
MiNK Therapeutics Reports Third Quarter 2023 Results
MiNK Therapeutics Insider Ups Holding During Year
See More Headlines
Receive INKT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MiNK Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/10/2023
Today
3/28/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:INKT
Fax
N/A
Employees
37
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$9.00
High Stock Price Target
$9.00
Low Stock Price Target
$9.00
Potential Upside/Downside
+889.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-22,460,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($0.52) per share

Miscellaneous

Free Float
28,519,000
Market Cap
$31.58 million
Optionable
No Data
Beta
0.12
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Garo H. Armen Ph.D. (Age 71)
    Executive Chairman
  • Dr. Jennifer S. Buell Ph.D. (Age 49)
    President, CEO & Director
    Comp: $812.78k
  • Dr. Marcus Antonius van Dijk Ph.D. (Age 62)
    Chief Scientific Officer
    Comp: $369.92k
  • Ms. Christine M. Klaskin (Age 58)
    Treasurer
    Comp: $27.24k
  • Ms. Heather Boussios
    General Counsel & Chief Compliance Officer
  • Joy Zhou Ph.D.
    Vice President & Head of CMC

INKT Stock Analysis - Frequently Asked Questions

Should I buy or sell MiNK Therapeutics stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MiNK Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" INKT shares.
View INKT analyst ratings
or view top-rated stocks.

What is MiNK Therapeutics' stock price target for 2024?

2 equities research analysts have issued 1 year target prices for MiNK Therapeutics' stock. Their INKT share price targets range from $9.00 to $9.00. On average, they predict the company's stock price to reach $9.00 in the next twelve months. This suggests a possible upside of 889.0% from the stock's current price.
View analysts price targets for INKT
or view top-rated stocks among Wall Street analysts.

How have INKT shares performed in 2024?

MiNK Therapeutics' stock was trading at $1.07 at the beginning of the year. Since then, INKT stock has decreased by 15.0% and is now trading at $0.91.
View the best growth stocks for 2024 here
.

Are investors shorting MiNK Therapeutics?

MiNK Therapeutics saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 46,500 shares, an increase of 12.6% from the February 29th total of 41,300 shares. Based on an average daily volume of 54,800 shares, the days-to-cover ratio is currently 0.8 days. Currently, 0.5% of the shares of the company are sold short.
View MiNK Therapeutics' Short Interest
.

When is MiNK Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our INKT earnings forecast
.

How were MiNK Therapeutics' earnings last quarter?

MiNK Therapeutics, Inc. (NASDAQ:INKT) announced its earnings results on Thursday, August, 10th. The company reported ($0.18) EPS for the quarter, beating analysts' consensus estimates of ($0.19) by $0.01. During the same period in the previous year, the business earned ($0.18) EPS.

When did MiNK Therapeutics IPO?

MiNK Therapeutics (INKT) raised $43 million in an initial public offering (IPO) on Friday, October 15th 2021. The company issued 3,333,334 shares at a price of $12.00-$14.00 per share.

Who are MiNK Therapeutics' major shareholders?

MiNK Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Citadel Advisors LLC (0.12%). Insiders that own company stock include Agenus Inc, Garo H Armen and Ulf Wiinberg.
View institutional ownership trends
.

How do I buy shares of MiNK Therapeutics?

Shares of INKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:INKT) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners